Key Drivers
- Strong liquidity
- High gross margins
- Large cash burn
AIAI Summary
Insmed has moved from a high‑risk biotech to a commercial‑plus‑pipeline story where near‑term valuation now hinges on ARIKAYCE/BRINSUPRI launch execution, payer coverage, and the upcoming ENCORE/CEDAR readouts—track quarterly revenue, gross‑to‑net trends, and burn rate as primary go/no‑go signals. A positive readout plus clear BRINSUPRI payer uptake would materially de‑risk the thesis; missed readouts or weaker reimbursement would likely trigger sharp re‑rating or dilution.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •High gross margins
- •Large cash burn
Despite strong liquidity and high gross margins, INSM is burning cash with steep operating losses, negative FCF and elevated leverage while trading at very rich valuation multiples.
Price Behavior
Key Price Behavior Insights:
- •Below SMA
- •Lower highs
- •Clustered support
INSM is in a short-term downtrend: last month's SMA (~$146.4) sits above the $136 close after a ~17.5% drop from the late‑Feb peak, with near-term support near $139 and resistance at $158–$165, so failure to reclaim $146–$150 keeps downside risk elevated.
Rapid ~17.5% fall from $164.91 to $136.00 over the last month indicating elevated volatility
Sentiment & News
Key News Insights:
- •Institutional inflows
- •Insider selling
- •Employee grants
Institutional buying (Artisan, Algert, BNS) amid CEO share sales, conference outreach, and employee inducement grants point to rising investor interest and portfolio reshuffling at Insmed in early 2026.
Overall this activity is likely supportive for liquidity and market interest but warrants caution due to insider sales and notable portfolio rotation
Similar Companies in Healthcare
Other companies in the same sector with AI ratings